RLA8 - A New and Highly Effective Quadruple PPARs-α/γ/δ and GPR40 Agonist to Reverse Nonalcoholic Steatohepatitis and Fibrosis

Journal of Pharmacology and Experimental Therapeutics - United States
doi 10.1124/jpet.118.255216
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Related search

Pioglitazone for Advanced Fibrosis in Nonalcoholic Steatohepatitis: New Evidence, New Challenges

Hepatology
MedicineHepatology
2017English

A New Method to Induce Nonalcoholic Steatohepatitis (NASH) in Mice

BMC Gastroenterology
MedicineGastroenterology
2019English

Association Between Diabetes, Family History of Diabetes, and Risk of Nonalcoholic Steatohepatitis and Fibrosis

Hepatology
MedicineHepatology
2012English

Gut Microbiota and Nonalcoholic Steatohepatitis

Folia Pharmacologica Japonica
Pharmacology
2018English

Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

Clinics in Liver Disease
Hepatology
2018English

New Clinical Score to Diagnose Nonalcoholic Steatohepatitis in Obese Patients

Diabetology and Metabolic Syndrome
Internal MedicineEndocrinologyMetabolismDiabetes
2011English

Myricetin Modulates Macrophage Polarization and Mitigates Liver Inflammation and Fibrosis in a Murine Model of Nonalcoholic Steatohepatitis

Frontiers in Medicine
Medicine
2020English

Nonalcoholic Steatohepatitis

English

Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis

Diabetes
Internal MedicineEndocrinologyMetabolismDiabetes
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy